



New Sandostatin LAR® Agreement with Novartis

Oncology Associates is pleased to announce its agreement with Novartis for Sandostatin LAR®. The terms of the new agreement became effective **April 1, 2004** and run through **December 31, 2004**.

All OA members in good standing are eligible for this agreement and can earn a Performance Rebate on Sandostatin LAR®. Novartis will pay OA Members the **Performance Rebate**, as set forth in the table below and calculated for each approved member equal to **3% on all purchases** of Sandostatin LAR® NDC's under this agreement from April 1, 2004 to December 31, 2004. Rebates will be earned monthly with the rebate period indicated in the table below and checks will be issued by OA within 90 days from the end of each month.

The information below outlines the maximum Sandostatin LAR Contract Benefit available:

Sandostatin LAR applicable period: April '04 – December '04

Discount Percent: 5.0%

Performance Rebate: 3.0%

Maximum Contract Benefit (Discount + Performance Rebate): 8.0%

Sandostatin LAR® Depot (octreotide acetate for injectable suspension) is indicated for the following:

- > Long-term maintenance therapy in acromegalic patients for whom medical treatment is appropriate and who have been shown to respond to and can tolerate Sandostatin® (octreotide acetate) Injection.
- > Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors in patients in whom initial treatment with Sandostatin® Injection has been shown to be effective and tolerated.
- > Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with Sandostatin® Injection has been shown to be effective and tolerated.

Product	Generic Name	NDC#	Discount %
Sandostatin LAR® Depot 10 mg	Octreotide acetate	0078-0340-84	5.0%
Sandostatin LAR® Depot 20 mg	Octreotide acetate	0078-0341-84	5.0%
Sandostatin LAR® Depot 30 mg	Octreotide acetate	0078-0342-84	5.0%

Please contact Oncology Associates at **888-732-7352** with any questions regarding the terms of this agreement.



Exciting Enhancements to the Roche Agreement

Oncology Associates is pleased to announce the following improvements to the Roche agreement for Kytril:

- > Start Date of July 1, 2004
- > The minimum annual 5HT₃ DDD dollars required for Super Tier pricing shall be significantly lowered from \$1,000,000 to \$500,000.
- > Kytril Market Share will be determined using DDD Dollars and is calculated as the sum of Kytril sales divided by the sum of all 5HT₃ Market sales.

Please contact Oncology Associates at 888-732-7352 for additional information on how you can get the greatest benefit out of your Roche agreement.

NDC	Package Size	Strength
00004-0239-09	1mg/mL 1mL Single Dose Vial	1mg/mL
00004-0240-09	1 mg/mL 4 mL Multi Dose Vial	1mg/mL

How Can OA Help You?

- > CALL AND LET US KNOW!
- > READ TIMELY FAX UPDATES
- > REVIEW SPECIAL MAILERS FROM OA
- > VISIT OAGPO.COM
- > IDENTIFY YOURSELF AS AN OA MEMBER TO ALL VISITING REPRESENTATIVES
- > ATTEND OA CONFERENCES